Clinical development & trial strategy
Translational & preclinical research
Mark L. Levitt MD PhD brings what few consultants can — two decades of pharmaceutical leadership combined with the scientific depth of an NIH-trained oncologist and researcher. LOA helps biotech and pharma companies develop oncology assets from preclinical strategy through clinical execution.
You have an innovative oncology asset. LOA helps you build the scientific and strategic foundation to develop it — from IND-enabling studies through late-phase clinical execution and regulatory strategy.
From biotech startups to Big Pharma and VCs — LOA has served over 23 client organizations globally. We specialize in companies with innovative, non–me-too ideas and the drive to develop them.
Mark Levitt brings what few consultants anywhere in the world can offer — the ability to combine clinical and basic science insights into a coherent strategic vision. NIH-trained, academically published, and with nearly two decades in pharmaceutical leadership, he has operated at the highest levels of drug development, business development, and oncology research.
As a Board Certified Medical Oncologist and Internist in both the US and Israel, with academic training at the NCI and industry experience at Teva, Inotek, RedHill, and EnGeneIC — his perspective is uniquely broad and deeply grounded.
LOA has provided consulting services to over 23 organizations — from early-stage Israeli biotech startups to Big Pharma. A specialty niche in the Israeli biotechnology sector, combined with global reach.